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Abstract In order to identify healthcare resource use patterns associated with chronic obstructive pulmonary disease 
(COPD), resource utilization (RU) data collection was integrated into a randomized, double-blind placebo-controlled 
study ofViozan TM (sibenadet HCI).This study enrolled patients with symptomatic, smoking-related COPD, randomized to 
receive sibenadet or placebo for a 52-week treatment period.A questionnaire stablishing typical pre-trial, COPD-related 
RU was completed by each patient. Subsequent data were collected by means of an Interactive Voice Response System 
(IVRS) at 30-day intervals (14 time points) during the study and in the follow-up period.The IVRS system facilitated data 
collection and minimized inconvenience to the patient. Compliance with the requirement o record details of the 
healthcare services during the year-long study was high. 
No overall trend for lower RU was associated with sibenadet therapy, which correlates with the lack of sustained clinical 
effect seen in studies conducted concurrently,These data do, however, provide valuable information on RU associated with 
COPD and insights into adjustments associated with changes in disease course. Physicians were seen to be the most 
common source of care for patients with COPD and more of the patients with severe COPD (stage III) than mild (stage I) 
were seen to utilize the most expensive resources (e.g. inpatient hospital care). For those patients who experienced an 
exacerbation during the trial (irrespective of treatment group), resource use was increased during the periods when an 
exacerbation was reported when compared with the periods before or after an exacerbation.The proportion of cases 
attending the physician doubled and with a trip to the Emergency Room (ER) increased approximately ninefold during the 
reporting period in which the exacerbation occurred compared with the previous month. 
This study has shown that use of an IVRS, even in elderly patients, is an effective means of gathering RU data over long 
periods.The study findings suggest hat the advent of effective therapeutic interventions, particularly any with the ability 
to minimize exacerbations and limit disease progression, could impact on the health care services used and potentially 
reduce associated costs. 
© 2003 Elsevier Science Ltd 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a 
major cause of morbidity and mortality worldwide; it is 
believed that around 16 million people suffer from 
COPD in the U.S.A. alone (I).As many patients remain 
undiagnosed, an accurate determination of global 
prevalence is extremely difficult but has been estimated 
to be around 4-6% in those over the age of 45 years (2). 
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COPD is a leading cause of death, predicted to increase 
in prevalence worldwide (3). 
COPD occurs primarily in elderly, long-term 
smokers and is characterized by the key symptoms of 
breathlessness, cough and sputum (4-5). The disease 
course of COPD is extremely slow, meaning that 
patients will suffer the symptoms of disease for many 
years or even decades. The associated economic 
impact is considerable although limited pharmaco- 
economic analyses have been performed and detailed 
information is available only from North America and 
some European countries (6). Published U.S data 
reported in 1993 estimated the total cost related to 
COPD management to be $23.9 billion. Direct medical 
costs accounted for 62% of the total, with 
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hospitalizations accounting for a substantial propor- 
tion of the direct medical cost (6). It is estimated that 
the direct costs of COPD are twice those of asthma 
(6). 
In contrast to other chronic conditions, the 
proportion of healthcare costs attributed to medication 
is relatively low for patients with COPD (7), the greatest 
proportion of direct costs associated with COPD being 
long-term oxygen therapy and hospitalization (7-9). 
A strong correlation between stage of disease and 
treatment costs has been demonstrated, with increased 
utilization of clinic, emergency department and hospital 
visits associated with a more advanced stage of disease 
(10). A proportion of these increased costs will be due 
to an increased frequency of exacerbations necessitating 
emergency visits or hospitalization amongst patients at a 
more severe stage of COPD (11). Previous studies in the 
U.S.A. have shown healthcare utilization among patients 
with COPD to be disproportionately distributed, with a 
small proportion of the patients (approximately 10%) 
accounting for at least half of the expenditure, with 
hospitalization being an important component of that 
expense (12-13). Supplemental home oxygen constitutes 
a large proportion of outpatient costs (7).The need for 
long-term treatment means that oxygen therapy, along 
with hospitalization, nursing home care, physician visits 
and medication are the major cost drivers in COPD (7). 
As requirement for these interventions increases with 
disease severity, disease stage can be considered to be a 
key factor in resource utilization (RU). 
Patients participating in a I-year safety study of the 
novel D 2 dopamine receptor, ~2-adrenoceptor agonist, 
Viozan TM (sibenadet HCI) were recruited to participate 
in a parallel RU study, the results of which are reported 
here.The objectives of this secondary investigation were 
twofold; first to identify overall RU in patients with 
symptomatic, smoking-related COPD and second to 
discern any differential RU associated with different 
treatment strategies. 
METHODS 
RU data were collected from patients participating in a 
long-term placebo-controlled safety study of sibenadet, 
the details of which are reported by Hiller etal. (14).The 
RU data collection process was designed to provide the 
means to collect not only overall COPD management- 
related RU patterns, but also health care service use by 
treatment arm. 
Clinical trial design 
Patient population 
The safety study recruited male and female patients 
(aged 40-80years) with stable, uncomplicated COPD 
(with symptoms for at least 2years). Subjects were 
required to be current or exsmokers with a smoking 
history of at least 15 pack-years (where I pack year = 20 
cigarettes smoked per day for l year or equivalent). 
Additional inclusion criteria were a forced expiratory 
volume in one second/forced vital capacity (FEVI/FVC) 
ratio of < 70%, and an FEV I 20-70% of predicted normal 
range. 
Patients not eligible for the study included those with 
other significant diseases, evidence of a COPD 
exacerbation in the previous 6weeks, previous 
participation in a clinical study of sibenadet, participation 
in any clinical study in the previous 3 months, laboratory 
abnormalities or use of disallowed medication. Patients 
were allowed to continue using inhaled anticholinergic 
agents, mucolytics, methylxanthines and corticosteroids, 
provided that the dose remained constant throughout 
the study. 
Study design 
RU data were collected from patients randomized to a 
double-blind, placebo-controlled study of sibenadet (14). 
The RU data were collected from patients recruited at 
43 centres in the U.S.A. Eligible patients were enrolled and 
entered a 2-week baseline assessment period. Disallowed 
medication was withdrawn and salbutamol inhalers were 
supplied for use as rescue medication when required. At 
the end of the baseline period, patients who had completed 
their diary card correctly and had not experienced COPD 
exacerbations were randomized to receive either 500 I~g 
(ex-actuator) sibenadet or placebo pressurized metered- 
dose inhaler (pMDI) three times daily for a total of 
52 weeks. At the end of the treatment period, sibenadet 
and placebo inhalers were withdrawn, and patients were 
required to continue using only rescue medication during a 
4-week follow-up period until the final clinic visit. Diary 
cards were completed by patients throughout the study to 
record use of study and rescue medication, changes in 
concomitant medication, and adverse events. 
The study was performed in accordance with the 
principles stated in the Declaration of Helsinki and 
approved by ethics committees at each centre.To ensure 
confidentiality throughout collection of RU data, patients 
were referred to by a patient identification umber only. 
Collection of healthcare RU data 
The primary objective for collecting RU data as part of 
the clinical study was to identify RU patterns in COPD 
by treatment arm in order to determine if any differential 
use profiles existed. 
Data collection procedure 
COPD-related healthcare RU data were collected on all 
patients randomized to treatment. At the end of the 
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baseline period, RU questionnaires were completed by 
the patients to record COPD-related medical care 
received in a typical month and health care service use 
(e.g. hospitalization, emergency room (ER) visit) in the 
3 months prior to the start of the clinical trial. The 
questionnaire recorded demographic information 
(gender, age, functional independence level, and regular 
oxygen use). The following healthcare services were 
summarized: physician, nurse, therapists (i.e. physical, 
occupational, respiratory), psychotherapist, or social 
worker visits; paid domestic help; COPD-related ER 
visits and acute hospital stays. 
RU data were subsequently collected at 30-day 
intervals (14 in total) during the treatment and follow-up 
periods of the trial. Patients were asked to report, by 
telephone, healthcare services u ed for the previous 
30-day reporting period. A healthcare resource use 
tracking aid and written instructions were provided to 
facilitate recall. The interactive voice response system 
(IVRS) was utilized by all patients with a touch-tone 
phone (97%). The remaining 3% of study patients 
reported their data via a telephone interview. 
RU data collection was designed and managed by Caro 
Research (Concord, MA, U.S.A.) who also conducted all 
RU-related analyses. 
Data from the clinical trial allowed further analyses by 
disease severity, disease duration and clinical 
exacerbations. COPD severity was noted as stage I (FEV I 
% predicted > 50), II (FEV 1% predicted 35-49) or III 
(FEV 1% predicted < 35) as defined by the American 
Thoracic Society (4). Clinical exacerbations were defined 
as worsening symptoms of COPD requiring drug therapy 
in addition to study medication (study drug and rescue 
medication) and doses of concomitant COPD 
medications. In addition, any adverse event description 
that contained both the words 'COPD' and 
'exacerbation' was also considered to be a relevant 
COPD exacerbation. 
Analyses 
The baseline characteristics are r ported by gender, age 
(< 65/_>65years), current smoking status, stage and 
duration of COPD. The proportions of patients using 
each service during a typical month before the trial and 
during the trial were determined and compared between 
treatment groups. For users of a service, the mean use 
per month was determined. In addition, analyses w re 
undertaken for the subgroup of patients experiencing 
exacerbations. 
Initial analyses employed the intention to treat (IT'I') 
principle with all data from the RU population included 
in all analyses irrespective of compliance with study 
medications or protocol deviations. 
RU was compared before, during and after a period 
when a clinical exacerbation of the disease was 
recorded.This required identification of the subgroup of 
the patients providing RU data that experienced an 
exacerbation (i.e. patients without an exacerbation are 
excluded) with RU data reported in the period before or 
after the exacerbation (i.e. some exacerbations were 
excluded). 
RESULTS 
Patient characteristics 
A total of 434 patients completed the pre-trial RU 
questionnaire; 41 patients dropped out of the trial before 
reporting any RU information by telephone. All 393 
remaining patients reported RU data at least once during 
the trial. Compliance with providing details of RU during 
the course of the study was high. Of chose who started 
the trial, 64.2% reported data for 12 or more periods. 
Data were reported for all 14 periods by 137 subjects 
(34.9%). Of the 72% who completed the trial and 
reported RU data, 89% provided data for 12 or more 
periods. Baseline demographic data (Table I) showed 
that the majority of patients reporting RU data were 
male, over 65 years of age and had been diagnosed with 
COPD within the last 5 years. 
Resource utilization results 
RU recorded at baseline (obtained from 434 patients 
completing the pretrial RU assessment questionnaire) 
indicated that before starting the trial the most 
frequently used services were medical doctor visits, 
which were reported by 16.2% of patients during the 
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past month, and approximately 13"6% used oxygen at 
least once each week.There were no differences in the 
pretrial RU profiles of the treatment groups, except that 
significantly more of the placebo group had typically 
visited a respiratory therapist. 
Resource use during the study period was obtained 
from 393 patients. Of the I1-1- population, 79% reported 
use of one of the resources at least once during the trial 
period. Physician visits were the most common resource 
used, with 72.5% reporting at least one visit (Table 2). 
Less than 5% of the patients visited each of the other 
health care professionals in each 30-day data-reporting 
period. Few patients visited a physical therapist (6"6%) 
once during the trial and < 2"3% received care at least 
once from a social worker, occupational therapist, or 
psychotherapist. During the course of the trial, a small 
group of patients were not able to receive all their 
medical care in an outpatient setting - 16.3% were 
admitted to hospital and 13.5% attended an emergency 
room. Paid housekeeping or domestic help services were 
used at least once during the trial by 7-9% of the 
patients, for an average of 12.2 hours per month. 
Few differences in RU were seen between patients 
randomized to placebo or sibenadet therapy. Differences 
were, however, seen in terms of physician and ER visits. 
Patients receiving sibenadet reported a lower rate of 
physician visits (68.4% vs. 80.8% for placebo, P=0.010) 
and a lower rate of ER visits than those receiving placebo 
(I 1.0% vs. 18"5%, P=0.042). 
Resource use and disease stage 
Patients with more severe disease (Stage III) were more 
than twice as likely to be using oxygen at least once 
during the trial as those at Stage I or II (30% vs. 13.9% for 
Stage I and 13.2% for Stage II, P < 0.00 I). More severe 
disease was also associated with an increased risk of an 
ER visit or hospitalization during the trial. Patients at 
Stage lll were more likely to report hospitalization 
(25-5% vs. 7.4% for Stage l and 13.9% for Stage II, 
P< 0-001) (Figure I) or an ER visit and hospitalization 
(I 5.6% vs. 2-8% for Stage I and 6-9% for Stage II, P=O.O01 )
during the same period. 
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Exacerbat ions and resource use 
From a subset of 184 patients who experienced an 
exacerbation during the trial period and provided RU 
data, information from 372 exacerbations were collected 
across both treatment groups. From these, data were 
collected from a period preceding the exacerbation in 
198 cases, during an exacerbation for 241 cases and after 
an exacerbation for 204 cases. Resource use was 
increased during the periods when an exacerbation was 
reported compared with the periods before or after an 
exacerbation (Figure 2).The proportion reporting use of 
any healthcare service increased from 43"9% of subjects 
in the period preceding, to 67.6% during the 
exacerbation (P < 0-0001). This increase was sustained 
post-exacerbation, when 52% of cases used at least one 
service. Physician visits increased from 27.3% to 55.2%, 
ER visits from 1.5% to 13.7% and hospitalizations from 
1.0% to 13"3%. 
DISCUSSION 
The primary objective of this study was to identify RU 
patterns by treatment arm in patients with COPD in 
order to determine if a differential cost profile could be 
established in a later analysis. Sibenadet therapy, however, 
failed to demonstrate significant efficacy benefits in any 
of the large-scale clinical studies conducted (I 4-16).The 
data collected during this study provide interesting 
additional information on RU associated with COPD and 
insights into adjustments associated with changes in 
disease course. Being part of a clinical study, the RU 
information obtained represents a well-defined patient 
group assessed under highly controlled conditions.While 
this situation is desirable for data collection, participation 
in a trial may also have influenced the RU profiles, partly 
due to the scheduled visits during the trial, and also due 
to the fact that patients were required to meet very 
specific inclusion and exclusion criteria for entry into the 
study.The RU profiles detailed here are, therefore, repre- 
sentative of the services used by this trial population, and 
may not be typical of the services used by all patients 
diagnosed with COPD. For example, patients with 
COPD commonly have comorbidities uch as congestive 
heart failure, and this has been shown to substantially 
influence health care service utilization and costs (12). 
Compliance with reporting RU data was good; almost 
two-thirds of the patients reported 12 or more periods 
worth of data and over a third of the patients provided 
all reports. Supplying a carefully designed tracking aid 
facilitated recall of the services used during the period 
and continued participation was encouraged by the 
convenience of using the IVRS. Although patient 
discontinuation from the clinical study of almost one 
third (14) may have introduced some bias into the RU 
estimates, compliance with reporting requirements will 
have limited the impact of drop-outs. 
Analysis of healthcare utilization confirmed that 
physicians are the most common source of care for 
patients with COPD; about one-third of the patients 
reported a physician visit in each 30-day reporting 
period. Additional RU was, however, generally low 
although our findings indicate that a small group of 
patients required inpatient care.This is consistent with 
other studies that found a small proportion of patients 
(approximately 10%) account for at least half the 
expenditure, hospitalization being an important 
component of that expenditure (6,12). As reported in 
previous studies (10) stage of disease was seen to be an 
important factor influencing use of services. Home 
oxygen therapy and hospitalization account for a 
substantial proportion of expenditure when caring for 
patients with COPD (7).This RU assessment has shown 
that three times as many patients at a more severe stage 
of disease (Stage III) compared with mild disease (Stage I) 
were hospitalized at least once during the study. As 
previously noted, oxygen use also increased with disease 
severity (10). 
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Patients with COPD experience exacerbations of 
their disease, which may be associated with bacterial or 
viral infections (4). Substantially higher RU was observed 
for all services (with the exception of oxygen use) during 
the period when an exacerbation was reported 
compared to before or after the exacerbation. During 
the period of an exacerbation the proportion reporting 
a physician visit was approximately twice that reported 
in the period prior to an exacerbation. In addition, 
approximately 13.7% reported an ER visit or 
hospitalization during an exacerbation period, at least a 
ninefold increase from the previous period. 
Exacerbations are therefore clearly associated with 
increased use of inpatient and outpatient services. 
Information on concomitant medication was not 
collected as part of this resource use study, but may have 
provided further insights into the exacerbation scenario. 
Although no cost analyses were performed as part of 
this study, it is possible to consider that effective therapy 
may have the potential to generate savings to justify the 
cost of a new treatment. In particular, treatment hat can 
effectively reduce the rate and severity of exacerbations 
is likely to reduce inpatient RU and increase use of less 
costly outpatient care. Such analyses should therefore 
form an important aspect of the overall assessment of 
future novel therapies, although longer-term studies that 
describe associated costs and the use of cost- 
effectiveness analyses will be required to adequately 
describe the cost implications of RU to payers. 
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